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OBJECTIVEdThere is limited evidence on how intensive multifactorial treatment (IT)
improves outcomes of diabetes when initiated in the lead time between detection by screening
and diagnosis in routine clinical practice. We examined the effects of early detection and IT of
type 2 diabetes in primary care on the prevalence of diabetic peripheral neuropathy (DPN) and
peripheral arterial disease (PAD) 6 years later in a pragmatic, cluster-randomized parallel group
trial.
RESEARCHDESIGNANDMETHODSdA stepwise screening program in 190 general
practices in Denmark was used to identify 1,533 people with type 2 diabetes. General prac-
tices were randomized to deliver either IT or routine care (RC) as recommended through
national guidelines. Participants were followed for 6 years and measures of DPN and PAD
were applied.
RESULTSdWe found no statistically signiﬁcant effect of IT on the prevalence of DPN and PAD
compared with RC. The prevalence of an ankle brachial index#0.9 was 9.1% (95%CI 6.0–12.2)
in the RC arm and 7.3% (5.0–9.6) in the IT arm. In participants tested for vibration detection
threshold and light touch sensation, the prevalence of a least one abnormal test was 34.8% (26.7–
43.0) in the RC arm and 30.1% (24.1–36.1) in the IT arm.
CONCLUSIONSdIn a population with screen-detected type 2 diabetes, we did not ﬁnd that
screening followed by IT led to a statistically signiﬁcant difference in the prevalence of DPN and
PAD 6 years after diagnosis. However, treatment levels were high in both groups.
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D iabetes is increasingly consideredsuitable for screening (1). However,even though modeling studies sug-
gest that screening may be cost effective,
there are several critical uncertainties (2).
In particular, there is limited evidence
that beneﬁt estimates obtained from stud-
ies of clinically detected type 2 diabetes
also apply to screen-detected populations.
The multicenter Anglo-Danish-Dutch
Study of Intensive Treatment in People
With Screen-Detected Diabetes in Pri-
mary Care (ADDITION) was set to obtain
this evidence base. The ADDITION study
showed that an intervention to promote
target-driven, intensive management of
patients with screen-detected type 2 diabe-
tes was associated with a nonstatistically
signiﬁcant 17% relative reduction in the
incidence of a composite cardiovascular
event end point over 5 years (3). There
is limited trial evidence regarding preven-
tion of diabetic peripheral neuropathy
(DPN) and peripheral arterial disease
(PAD) in people with diabetes. As current
knowledge on PAD and DPN in diabetes
has been gained in patients with clinically
diagnosed and sometimes longstanding
diabetes, and as the prevalence of PAD
and DPN in patients with screen-detected
diabetes is unknown, our aim was to de-
scribe the effect of early detection and in-
tensive multifactorial treatment (IT) on
the prevalence of DPN and PAD in pa-
tients with screen-detected type 2 diabe-
tes in the Danish arm of the ADDITION
study.
RESEARCH DESIGN AND
METHODS
Design
The design and rationale of the ADDITION
study have been reported (4). In brief,
ADDITION-Denmark consists of two
phases: 1) a screening phase and 2) a prag-
matic, cluster-randomized parallel group
trial. In ﬁve regions of Denmark, 744 gen-
eral practices were invited to participate
and 190 agreed and were randomized to
screening plus routine care (RC) of diabe-
tes or screening followed by IT. Random-
ization was stratiﬁed by region and the
number of full-time general practitioners
per practice.
A population-based stepwise screen-
ing program among people aged 40–69
years without known diabetes was under-
taken, and individuals were diagnosed
with diabetes according to World Health
Organization (WHO) criteria, as previously
described (5). Overall 1,533 (RC, 623; IT,
910) eligible participants with screen-
detected diabetes agreed to take part in the
trial. After an average of 6 years of follow-
up, 1,278 participants were re-examined.
One hundred eight people were only seen
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by their own general practitioner and nine
people were not examined with the tests
included in the present analysis and did
not answer the questionnaires. These par-
ticipants were excluded from our analysis,
yielding a study sample of 1,161 partici-
pants for the analysis presented in this pa-
per. Supplementary Fig. A1 displays the
practice and participant ﬂow.
Intervention
The speciﬁc characteristics of the inter-
ventions to promote IT have been de-
scribed previously in detail (4). The
purpose of the IT was to provide the
best possible evidence-based treatment
in primary care. We aimed to educate
and support general practitioners and
practice nurses in target-driven manage-
ment (using medication and promotion
of healthy lifestyle) of hyperglycemia,
blood pressure, and cholesterol, based
on the stepwise regimen used in the
Steno-2 study (6). Intensive treatment
was promoted through the addition of
several features to existing diabetes care.
Practice staff was provided with educa-
tional materials for patients, and patients
were sent reminders if annual check-up
appointments were overdue. Practices re-
ceived additional funding to support the
delivery of extra care added to the usual
care and consultations. All treatment tar-
gets and algorithms were based on evi-
dence from randomized controlled trials
demonstrating the beneﬁts of IT on car-
diovascular risk factors in people with
type 2 diabetes (3) and are displayed in
Supplementary Table A2. Although tar-
gets for treatment were speciﬁed and
classes of medication recommended, de-
cisions on prescriptions, including choice
of individual drugs, were made by practi-
tioners and patients.
In the RC group, general practitioners
were only provided with diagnostic test
results. Patients with screen-detected di-
abetes received the standard pattern of
diabetes care according to the Danish
national recommendations (7,8).
Measurements
Health assessments at baseline and follow-
up included biochemical, anthropometric,
and questionnaire measures and were
undertaken by centrally trained staff un-
aware of study group allocation, according
to standard operating procedures. Blood
pressure was calculated as the mean of
three measurements performed after at
least 10-min rest, while participants were
seatedwith the cuff on the right arm resting
at the level of the heart, usingOmron blood
pressure recorders. Height andweightwere
measured in light indoor clothing, without
shoes, using a ﬁxed rigid stadiometer and
a Tanita scale, respectively.
All biochemical measures were ana-
lyzed at baseline and follow-up at
the Aarhus University Hospital and
Steno Diabetes Center. The speciﬁc an-
alyses have been described previously.
Microalbumiuria was deﬁned as an al-
bumin/creatinin ratio on spot urine:
men, 2.5–25 mg/mmol; women, 3.5–
25 mg/mmol; macroalbuminuria, .25
mg/mmol (9).
Light touch sensory testing was per-
formed after a standardized protocol at
four test sites on each foot (plantar aspect
of the great toe and ﬁrst, third, and ﬁfth
metatarsal heads) using a Semmes-
Weinstein 10 g/5.07 monoﬁlament
(Bailey Instruments, Manchester, U.K.).
Inability to feel one or more of the test
sites was considered to be abnormal (10).
This is a single set level used to detect
unequivocal insensitivity. Vibration de-
tection threshold (VDT) was determined
on the dorsal side of the great toe proxi-
mal to the nail on both feet using a CASE
IV and the 4-2-1 stepping algorithm
(11), following a standard protocol. If
the patient failed to comply with the
null stimuli twice, the test was rerun
once after reinstruction of the patient. If
the patient again did not comply with the
null value twice, the test on that foot was
aborted. The CASE IV system uses a set of
25 standardized vibratory levels, and for
each test the computer calculates the “just
noticeable difference” (JND) from the sub-
ject’s responses. If the participant was un-
able to detect the highest vibration level,
VDT was set at 26 JND. The CASE IV sys-
tem also expresses the VDT values in nor-
mal deviates and percentiles as compared
with a normal population based on age,
sex, height, and weight. Values $95th
percentile were considered abnormal (12).
Ankle brachial index (ABI) was measured
by trained technicians using a Doppler
MiniD900 med Huntleigh Transducer
EZ8 Widebeam. After a 10-min rest in su-
pine position, brachial systolic blood
pressure was measured twice on both
arms. Then the distal systolic blood pres-
sure was determined twice (a third time if
there was more than 10mmHg difference)
in the arteria dorsalis pedis and the arteria
tibialis posterior, alternating on each foot.
ABI for each foot was calculated from the
highest distal blood pressure divided by
the highest brachial blood pressure from
either side (13). Low ABI was deﬁned as
0.9 or less (13).
Standardized self-report question-
naires were used to collect information
on socio-demographic characteristics
(education, employment, and ethnicity),
lifestyle habits (smoking status and al-
cohol consumption), and self-reported
cardiovascular disease (previous myo-
cardial infarction, stroke, or operation/
instrumentation on the heart). The patients
were asked to answer the questionnaire
part of theMichiganNeuropathy Screening
Instrument (MNSI) and scored accord-
ingly. A score $7 was considered abnor-
mal (14). Patients also completed the
Brief Pain Inventory short form (15). Pa-
tients were deﬁned as having painful di-
abetic neuropathy if they indicated
having pain in both legs (from knees
down) and/or both arms (from elbow
down).
ABI was done on all patients in
three centers (Holstebro, Aarhus, and
Copenhagen), and it was possible to cal-
culate ABI in both legs in 836 out of 863
patients. Monoﬁlament was done on all
patients in two centers (Aarhus and
Steno, 635 participants); 618 had data
from all eight test sites. CASE IV was
introduced in the follow-up examination
from 8 September 2009 in Aarhus and
from 22 September 2009 at Steno Diabe-
tes Center. Three hundred ninety-nine
participants were examined with CASE
IV, in 28 of whom data were not obtained
from both feet (20 aborted tests due to
incompliance with null stimuli, and 8 had
different disabilities, making CASE IV
impossible to test in both legs). Forty-six
participants were not measured with CASE
IV even though themachine was available.
One thousand one hundred forty eight
participants returned the supplementary
questionnaire containing the Michigan
neuropathy questionnaire and Brief Pain
Inventory short form.
The study was approved by local
ethics committees in each center and
was conducted in accordance with the
principles of the 1996 Helsinki Decla-
ration. All participants provided in-
formed consent.
Statistical analysis
Patient characteristics at baseline and at
follow-up are presented as unadjusted
means or, in case of skewed distributions,
as medians. Patient groups that were ex-
amined with different measures (CASE IV,
monoﬁlament, or ABI) were compared
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with all examined patients with the use of
Student t test or the Mann-Whitney U test
where appropriate. In case of unequal var-
iances, means were compared by ap-
proximate inference based on the t
distribution. Participants with missing
values (CASE IV, monoﬁlament, or ABI)
were compared with persons without
missing values. Participants with an aborted
test on CASE IV were compared with par-
ticipants without an aborted test. The
prevalence for each treatment group of
DPN and PAD was calculated as the num-
ber of participants with abnormal tests di-
vided by the number who participated in
that speciﬁc test and did not have a miss-
ing value. Data are presented with 95%CI.
Odds ratios of an effect of IT as compared
with RC were calculated using logistic re-
gression taking cluster effect (general
practitioner practice) into account. The
mean of the normal deviates of VDT in
each intervention group was compared
using Student t test. Statistical analyses
were performed with Stata software (ver-
sion 11, StataCorp LP, College Station,
TX).
RESULTSdBaseline characteristics are
shown in Table 1. The average follow-up
time was 5.8 years and 5.9 years for RC
and IT, respectively. Median HbA1c did
not change over the follow-up period
in either group, but there was a similar
signiﬁcant decline in systolic blood
pressure and total cholesterol in both
groups. There was an overall increase in
the proportion of participants using med-
ication during the follow-up time. In the
RC group, the proportion taking antihy-
pertensive drugs increased from 44 to
77% at follow-up, whereas lipid-lowering
drugs increased from 19 to 73%. In the IT
group, the corresponding proportions in-
creased from 47 to 80% and from 23 to
81%. At follow-up, antiglycemic drugs
were taken by 52% in the RC group and
63% in the IT group. Numbers of smokers
signiﬁcantly declined in both groups with
no difference between groups, and the to-
tal alcohol consumption also declined.
There was no change in BMI from base-
line. Patient characteristics of participants
at follow-up are summarized in Supple-
mentary Table A3.
We found no substantial differences
between subgroups and the total patient
population, and no differences between
participants with missing values com-
pared with participants with no missing
values, except for a few small differences
in the CASE IV subgroup. The CASE IV–
examined group was slightly younger
(RC, 58.5 years; IT, 58.3 years at baseline)
and had a shorter diabetes duration (RC,
5.1 years; IT, 5.4 years). The 46 patients
not tested with CASE IV, even though the
test was available at that time, had a sig-
niﬁcantly higher BMI and larger waist cir-
cumference. The 31 tested patients with
missing data on CASE IV were signiﬁ-
cantly older but otherwise did not differ
from the other patients tested with CASE
IV (data not shown).
The prevalence of low ABI and dif-
ferent measures of DPN are presented in
Table 2. The effect of intervention is
expressed as an odds ratio and presented
in Fig. 1. The means of the normal devi-
ates of VDT in each foot were higher in
the RC group compared with the IT
group, but the difference was not statisti-
cally signiﬁcant.
CONCLUSIONSdWe found no sta-
tistically signiﬁcant effect of IT in general
practice, delivered through education and
support of general practitioners and prac-
tice nurses in evidence-based, target-
driven management and strict treatment
targets/algorithms, on the prevalence ofDPN
and PAD in people with screen-detected
type 2 diabetes as compared with RC
delivered according to the national rec-
ommendations.
Intervention studies in people with
type 2 diabetes have so far only found
modest effects on the prevention of DPN.
The UK Prospective Diabetes Study
indicated a beneﬁt of tighter glycemic
control on microvascular complica-
tions, but there was no effect on surro-
gate end points of DPN (16). In the
Action to Control Cardiovascular Risk
in Diabetes (ACCORD) trial, intensive
glycemic control only had a modest pos-
itive impact on the development of neu-
ropathy (17), with a signiﬁcant difference
between treatment groups in light touch
measuredwithmonoﬁlament but nodiffer-
ences inMNSI.2 or loss of vibration sense
measuredwith a 128-Hz tuning fork alone.
In the Steno-2 study, there was no differ-
ence between the treatment groups in the
development of peripheral neuropathy
measured with biothesiometry (6).
With regard to treatment, the inference
from the UK Prospective Diabetes Study
was that dyslipidemia and blood pres-
sure were potentially modiﬁable risk fac-
tors for the development of peripheral
Table 1dPatient characteristics at baseline
Patient characteristics RC IT
No. of patients 459 702
Male, N (%) 269 (59) 421 (60)
Age (years) 59.9 (6.8) 59.6 (6.9)
Glycosylated hemoglobin
(% of hemoglobin)* 6.4 (6.0; 7.0) 6.4 (6.0; 7.0)
Systolic blood pressure
(mmHg) 149.8 (19.3) 147.0 (19.1)
Diastolic blood pressure
(mmHg) 88.3 (11.3) 87.3 (10.6)
Weight (kg) F: 82.8 (17.0); M: 93.7 (15.9) F: 84.6 (18.3); M: 94.2 (15.9)
Height (cm) F: 162.6 (5.9); M: 175.6 (6.7) F: 163.7; M: 175.9 (6.7)
BMI F: 31.2 (6.0); M: 30.4 (4.4) F: 31.5 (6.5); M: 30.4 (3.4)
Total cholesterol (mmol/L) 5.77 (1.14) 5.58 (1.08)
HDL (mmol/L) 1.40 (0.34) 1.36 (0.36)
Triglycerides (mmol/L)* 1.6 (1.1; 2.4) 1.6 (1.1; 2.4)
Smoking daily, N (%) 134 (30) 215 (31)
Smoking less than daily, N (%) 169 (37) 271 (39)
Alcohol (units per week)* 6 (2; 14) 6 (2; 14)
Microalbuminuria, N (%) 52 (13) 78 (13)
Macroalbuminuria, N (%) 6 (2) 14 (2)
Antihypertensive drugs (%) 200 (44) 333 (47)
Lipid-lowering drugs (%) 87 (19) 162 (23)
Data are mean (SD), unless otherwise indicated. Patient characteristics at baseline of participants in the
Danish arm of ADDITION, who completed a neuropathy questionnaire and/or were tested for DPN or PAD at
follow-up. *Median (25th; 75th percentile). F, female; M, male.
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Neuropathy and arterial disease in diabetes
vascular disease in people with type 2
diabetes (18). Prospective data from
the Fremantle Diabetes study suggested
that treatment with statins or ﬁbrates
may protect against the development
of DPN (19).
In our study of patients with screen-
detected diabetes in primary care, we did
not ﬁnd that IT had a signiﬁcant impact
on the prevalence of DPN or PAD. How-
ever, all observed risk estimates favored
multifactorial intervention at a nonstatis-
tically signiﬁcant level. This ﬁndingmight
be due to the relatively early stage in the
disease process at which patients with
previously undiagnosed diabetes are
picked up by screening. It is conceivable
that at this stage where the progression of
the disease process underlying PAD and
DPN is also at its initial stages, a longer
duration of IT is necessary to observe an
effect. A future repeated examination of
our participants after a longer follow-up
period will show whether this is the case.
It should also be remarked that in the
ADDITION study, which was pragmatic
in design, both treatment groups saw a
marked improvement in treatment be-
tween baseline and follow-up as general
population treatment guidelines devel-
oped in the same time period (7,8). Con-
sequently, the treatment levels did not
differ as much between RC and IT groups
as was expected at study inception.
Current knowledge on PAD and DPN
in diabetes has been gained in patients
with traditionally diagnosed and some-
times longstanding diabetes. Reported
prevalence of DPN and PAD estimates
vary widely, most likely depending on
differences in patient selection, deﬁnition,
and methods of assessment. In Germany,
the MONICA/KORA Augsburg surveys
found the prevalence of DPN to be 28%
using the MNSI score .2, and the preva-
lence of ABI ,0.9 to be 16% in 195 pa-
tients with diabetes (20). At baseline in the
Australian Fremantle Diabetes study, the
prevalence of PAD (ABI,0.9) was 13.6%
in 1,181 patients assessed for PAD, but the
authors state that this is a conservative es-
timate, as 113 unclassiﬁed patients had
higher levels of risk factors (21). In the
same cohort, the prevalence of DPN using
MNSI score.2 was 30.9% (19). A recent
Swedish population–based study includ-
ing 156 patients found a prevalence of
DPN of 34% based on inability to feel
three out of four test sites with the mono-
ﬁlament or feel a neurothesiometer at a cut
point of .25 V (22).
A prevalence study in a U.K. general
practice reported the prevalence of pain-
ful diabetic neuropathy to be 26.4% (23),
but estimates on the prevalence of painful
neuropathy are sparse and vary from 8 to
26% in diabetic populations (24).
It is challenging to compare preva-
lences, especially DPN. But having all
objections in mind, our prevalences of
PAD and different measures of DPN in
our RC group seem slightly lower than
previously reported in other studies. This
could be a reﬂection of screening identifying
patients earlier in the trajectory of diabe-
tes and/or that the overall diabetes treat-
ment has improved. However, it is more
important to stress that our ﬁndings
show that even in this group of patients
at an early stage of type 2 diabetes, DPN
and PAD are present in a sufﬁciently large
proportion of patients to warrant close
clinical attention.
ADDITION-Europe is the ﬁrst inter-
national study on the effects of early
detection and IT of type 2 diabetes. Only
the ADDITION-Denmark population was
examined for PAD and DPN, and this
study, presenting prevalence in a screen-
detected population, is therefore unique.
All patients were identiﬁed and treated in
primary care, and the trained personnel
used broadly accepted and standardized
methods for diagnosis. This study there-
fore provides a solid overview of the size
of the problem of PAD and DPN in this
highly relevant population. At baseline
there was a very low level of retinopathy
(25), but we did not measure our outcome
characteristics during the baseline assess-
ment and can therefore not calculate in-
cidence rates. However, we can assume
that the prevalence of abnormal DPN
and PAD at baseline was equally distrib-
uted among the randomization groups.
The reported prevalence differences can
therefore be interpreted as differences in
cumulative incidence during the follow-
up period.
Our study has some selection prob-
lems. More patients were included in the
intensive care groups, even though there
was no difference in number and types of
practices in the randomization groups.
Randomization of practices was per-
formed before the screening and inclusion
of patients started. But it seems that the
intervention, which included training
doctors and nurses in diabetes treatment,
enhanced the focus in the IT group on
screening and including patients. Not all
patients were tested with all of our mea-
sures, but, except for the CASE IV sub-
group, we found no substantial difference
between those with and without measure-
ment. We are therefore conﬁdent that the
ﬁndings in these groups can be considered
representative for all included patients.
The patients tested with CASE IV were
slightly younger with shorter diabetes
duration. As older age and longer diabetes
duration are associated with higher levels
of DPN, it is possible that our results on
VDT slightly underestimate the preva-
lence in both treatment groups. It is also
possible that the small number of aborted
Table 2dPrevalence (% of examined population) of different measures of DPN and
low ABI in RC or IT group
Variable N RC (95% CI) IT (95% CI)
ABI #0.9 (%) 329/507 9.1 (6.0; 12.2) 7.3 (5.0; 9.6)
Light touch, 1/8 (%) 231/387 20.3 (15.3; 26.1) 17.8 (14.1; 22.0)
VDT, .95th percentile (%) 136/235 25.7 (18.3; 33.2) 22.6 (17.2; 28.1)
Light touch + VDT (%) 135/229 34.8 (26.7; 43.0) 30.1 (24.1; 36.1)
MNSI Qst, cut $7 430/656 9.3 (6.5; 12.1) 8.7 (6.5; 10.9)
Pain (%) 400/581 4.5 (2.5; 6.5) 4.6 (2.9; 6.4)
Light touch sensation tested with 10 g monoﬁlament. MNSI Qst, MNSI questionnaire; pain, distal peripheral
diabetic pain deﬁned by self-reported bilateral pain distal from knees or elbows.
Figure 1dEffect of IT in general practice as
compared with RC expressed in odds ratios
taking cluster effect into account. Light touch
sensation tested with 10 g monoﬁlament.
MNSI Qst, MNSI questionnaire $7; pain,
distal peripheral diabetic pain deﬁned by self-
reported bilateral pain distal from knees or
elbows.
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VDT tests could be associated with de-
creased or eradicated sensibility and
therefore caused a slight underestimation
of the prevalence of VDT. Ideally, sum-
med nerve conduction measures would
have been the most objective criterion of
DPN.
In a population of people with screen-
detected type 2 diabetes, education and
support of general practitioners and
practice nurses in evidence-based, target-
driven management and strict treatment
targets/algorithms did not cause a statis-
tically signiﬁcant difference in the prev-
alence of DPN and PAD 6 years after
diagnosis, as compared with RC deliv-
ered according to the national recommen-
dations. The high prevalence of PAD and
different measures of DPN in our RC
group seem to be only slightly lower
than previously reported values among
people with clinically diagnosed diabetes.
As both DPN and PAD are associated with
the development of foot ulcers and car-
diovascular disease, clinicians should be
aware of these high prevalences when
dealing with patients with screen-detected
diabetes.
AcknowledgmentsdADDITION-Denmark
was supported by the National Health Services
in the counties of Copenhagen, Aarhus, Ring-
købing, Ribe, and South Jutland in Denmark;
the Danish Council for Strategic Research; the
Danish Research Foundation for General Prac-
tice; Novo Nordisk Foundation; the Danish
Center for Evaluation and Health Technology
Assessment; the Diabetes Fund of the National
Board of Health; the Danish Medical Re-
search Council; and the Aarhus University
Research Foundation. The trial has been
given unrestricted grants from Novo Nordisk
AS, Novo Nordisk Scandinavia AB, Novo
NordiskUK, ASTRADenmark, Pﬁzer Denmark,
GlaxoSmithKline Pharma Denmark, Servier
Denmark A/S, and HemoCue Denmark A/S.
Parts of the grants from Novo Nordisk Foun-
dation, Danish Council for Strategic Research,
and Novo Nordisk were transferred to the
other centers. K.B.-J. holds stock in Novo
Nordisk. No other potential conﬂicts of in-
terest relevant to this article were reported.
M.C. wrote the manuscript and collected
and researched data. N.E. and D.R.W. col-
lected data and reviewed and edited the
manuscript. K.B.-J. and T.L. designed the
study, reviewed and edited the manuscript,
and obtained the grants. A.S. designed the
study, collected data, reviewed and edited the
manuscript, and obtained the grants.
Parts of this study were presented in oral
form at the 71st Scientiﬁc Sessions of the
American Diabetes Association, San Diego,
California, 24–28 June 2011.
References
1. WarehamNJ, Grifﬁn SJ. Should we screen
for type 2 diabetes? Evaluation against
National Screening Committee criteria.
BMJ 2001;322:986–988
2. Glümer C, Yuyun M, Grifﬁn S, et al. What
determines the cost-effectiveness of
diabetes screening? Diabetologia 2006;49:
1536–1544
3. Grifﬁn SJ, Borch-Johnsen K, Davies MJ,
et al. Effect of early intensivemultifactorial
therapy on 5-year cardiovascular out-
comes in individuals with type 2 diabetes
detected by screening (ADDITION-
Europe): a cluster-randomised trial. Lancet
2011;378:156–167
4. Lauritzen T, Grifﬁn S, Borch-Johnsen K,
Wareham NJ, Wolffenbuttel BH, Rutten G;
Anglo-Danish-Dutch Study of Inten-
sive Treatment in People with Screen-
Detected Diabetes in Primary Care. The
ADDITION study: proposed trial of the
cost-effectiveness of an intensive multi-
factorial intervention on morbidity and
mortality among people with type 2 di-
abetes detected by screening. Int J Obes
Relat Metab Disord 2000;24(Suppl. 3):
S6–S11
5. Sandbaek A, Grifﬁn SJ, Rutten G, et al.
Stepwise screening for diabetes identiﬁes
people with high but modiﬁable coronary
heart disease risk. The ADDITION study.
Diabetologia 2008;51:1127–1134
6. Gaede P, Vedel P, Larsen N, Jensen GV,
Parving HH, Pedersen O. Multifactorial
intervention and cardiovascular disease
in patients with type 2 diabetes. N Engl
J Med 2003;348:383–393
7. Royal College of General Practitioners
in Denmark. Type 2 Diabetes in General
PracticedDiagnosis and Treatment. Copen-
hagen, Denmark, Royal College of General
Practitioners, 1999
8. Royal College of General Practitioners
in Denmark. Type 2 Diabetes in General
PracticedAn Evidence Based Guideline.
Copenhagen, Denmark, Royal College of
General Practitioners, 2004
9. Mogensen CE. Microalbuminuria in per-
spectives. In Diabetic Renal-Retinal Syn-
drome: Pathogenesis and Management,
Update 2002. Friedman EA, L’Esperance
FA, Eds. London, Klüwer, 2002, p. 105–
119
10. Feng Y, Schlosser FJ, Sumpio BE. The
Semmes Weinstein monoﬁlament exami-
nation as a screening tool for diabetic
peripheral neuropathy. J Vasc Surg 2009;
50:675–682
11. Dyck PJ, O’Brien PC, Kosanke JL, Gillen
DA, Karnes JL. A 4, 2, and 1 stepping al-
gorithm for quick and accurate estimation
of cutaneous sensation threshold. Neu-
rology 1993;43:1508–1512
12. Dyck PJ, O’Brien PC, Litchy WJ, Harper
CM, Daube JR, Dyck PJ. Use of percentiles
and normal deviates to express nerve
conduction and other test abnormalities.
Muscle Nerve 2001;24:307–310
13. Hirsch AT, Haskal ZJ, Hertzer NR, et al.,
American Association for Vascular Sur-
gery; Society for Vascular Surgery; Society
for Cardiovascular Angiography and In-
terventions; Society for Vascular Medicine
and Biology; Society of Interventional Ra-
diology; ACC/AHA Task Force on Practice
Guidelines (Writing Committee to De-
velop Guidelines for the Management of
Patients With Peripheral Arterial Disease);
American Association of Cardiovascular
and Pulmonary Rehabilitation; National
Heart, Lung, and Blood Institute; Society
for Vascular Nursing; TransAtlantic Inter-
Society Consensus; Vascular Disease
Foundation. ACC/AHA 2005 Practice
Guidelines for the management of patients
with peripheral arterial disease (lower ex-
tremity, renal, mesenteric, and abdominal
aortic): a collaborative report from the
American Association for Vascular Sur-
gery/Society for Vascular Surgery, Society
for Cardiovascular Angiography and In-
terventions, Society for Vascular Medicine
and Biology, Society of Interventional Ra-
diology, and the ACC/AHA Task Force
on Practice Guidelines (Writing Com-
mittee to Develop Guidelines for the
Management of Patients With Periph-
eral Arterial Disease): endorsed by the
American Association of Cardiovascular
and Pulmonary Rehabilitation; National
Heart, Lung, and Blood Institute; Society
for Vascular Nursing; TransAtlantic Inter-
Society Consensus; and Vascular Disease
Foundation. Circulation 2006;113:e463–
e465
14. Feldman EL, Stevens MJ, Thomas PK,
Brown MB, Canal N, Greene DA. A prac-
tical two-step quantitative clinical and
electrophysiological assessment for the
diagnosis and staging of diabetic neu-
ropathy. Diabetes Care 1994;17:1281–
1289
15. Cleeland C. Pain assessment in cancer. In
Effect of Cancer on Quality of Life. Osobo D,
Ed. Boca Raton, FL, CRC Press, 1991,
p. 293–305
16. UK Prospective Diabetes Study (UKPDS)
Group. Intensive blood-glucose control
with sulphonylureas or insulin compared
with conventional treatment and risk of
complications in patients with type 2 di-
abetes (UKPDS 33). Lancet 1998;352:
837–853
17. Ismail-Beigi F, Craven T, Banerji MA,
et al.; ACCORD trial group. Effect of
intensive treatment of hyperglycaemia
on microvascular outcomes in type 2
diabetes: an analysis of the ACCORD
randomised trial. Lancet 2010;376:
419–430
18. Adler AI, Stevens RJ, Neil A, Stratton IM,
Boulton AJ, Holman RR. UKPDS 59: hy-
perglycemia and other potentially modi-
ﬁable risk factors for peripheral vascular
2248 DIABETES CARE, VOLUME 34, OCTOBER 2011 care.diabetesjournals.org
Neuropathy and arterial disease in diabetes
disease in type 2 diabetes. Diabetes Care
2002;25:894–899
19. Davis TM, Yeap BB, Davis WA, Bruce DG.
Lipid-lowering therapy and peripheral
sensory neuropathy in type 2 diabetes: the
Fremantle Diabetes Study. Diabetologia
2008;51:562–566
20. Ziegler D, Rathmann W, Meisinger C,
Dickhaus T, Mielck A; KORA Study
Group. Prevalence and risk factors of
neuropathic pain in survivors of myo-
cardial infarction with pre-diabetes and
diabetes: the KORA Myocardial Infarction
Registry. Eur J Pain 2009;13:582–587
21. NormanPE,DavisWA,BruceDG,DavisTM.
Peripheral arterial disease and risk of car-
diac death in type 2 diabetes: the Fre-
mantle Diabetes Study. Diabetes Care
2006;29:575–580
22. Kärvestedt L, Mårtensson E, Grill V,
et al. Peripheral sensory neuropathy as-
sociates with micro- or macroangio-
pathy: results from a population-based
study of type 2 diabetic patients in
Sweden. Diabetes Care 2009;32:317–
322
23. Davies M, Brophy S, Williams R, Taylor A.
The prevalence, severity, and impact
of painful diabetic peripheral neuropathy
in type 2 diabetes. Diabetes Care 2006;29:
1518–1522
24. Ziegler D. Painful diabetic neuropathy:
treatment and future aspects. Diabetes
Metab Res Rev 2008;24(Suppl. 1):S52–
S57
25. Bek T, Lund-Andersen H, Hansen AB,
Johnsen KB, Sandbaek A, Lauritzen T.
The prevalence of diabetic retinopathy
in patients with screen-detected type
2 diabetes in Denmark: the ADDITION
study. Acta Ophthalmol 2009;87:270–
274
care.diabetesjournals.org DIABETES CARE, VOLUME 34, OCTOBER 2011 2249
Charles and Associates
